Trastuzumab deruxtecan as standard of care for second-line treatment of metastatic HER2-positive breast cancer
2023
Abstract
Each year, approximately 15% of breast cancer patients are informed that their tumor is HER2-positive. Overexpression or amplification of the HER2 neu receptor signifies a poorer prognosis for the disease, but it also serves as a target for anti-HER2 therapies, which have fundamentally transformed the fate of these patients.
The ability to use anti-HER2 antibody-drug conjugates and cytostatic drugs in the treatment of HER2-positive breast cancer has a positive impact on the prognosis of patients with this disease in the metastatic phase.